ELI LILLY AND COMPANY OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax
ELI LILLY AND COMPANY (LLY) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax of -$7.10 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax · last filed 2025-02-19
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2016-12-31 was $282.50M, a 333.95% increase year-over-year.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2016-09-30 was -$600.00K.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2016-06-30 was $15.60M.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2015-12-31 was $65.10M, a 17.49% decline year-over-year.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2024 was -$7.10M, a 150.35% decline from fiscal 2023.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2023 was $14.10M.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2022 was -$53.20M.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2021 was -$15.90M, a 211.97% decline from fiscal 2020.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$7.10M 10-K · filed 2025-02-19 | |||
| 2023-12-31 | $14.10M 10-K · filed 2025-02-19 | |||
| 2022-12-31 | -$53.20M 10-K · filed 2025-02-19 | |||
| 2021-12-31 | -$15.90M 10-K · filed 2024-02-21 | |||
| 2020-12-31 | $14.20M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $34.40M 10-K · filed 2022-02-23 | |||
| 2018-12-31 | -$8.80M 10-K · filed 2021-02-17 | |||
| 2017-12-31 | -$181.30M 10-K · filed 2020-02-19 | |||
| 2016-12-31 | $282.50M derived: 8-K 12 month − 10-Q 9 month · filed 2019-10-24 | $281.90M derived: sum of 2 quarters · filed 2019-10-24 | $297.50M derived: sum of 3 quarters · filed 2019-10-24 | $303.00M 8-K · filed 2019-10-24 |
| 2016-09-30 | -$600.00K 10-Q · filed 2016-10-28 | $15.00M derived: sum of 2 quarters · filed 2016-10-28 | $20.50M 10-Q · filed 2016-10-28 | |
| 2016-06-30 | $15.60M 10-Q · filed 2016-07-28 | $21.10M 10-Q · filed 2016-07-28 | ||
| 2015-12-31 | $65.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | -$79.90M derived: sum of 2 quarters · filed 2018-02-20 | -$119.80M derived: sum of 3 quarters · filed 2018-02-20 | -$138.10M 10-K · filed 2018-02-20 |
| 2015-09-30 | -$145.00M 10-Q · filed 2016-10-28 | -$184.90M derived: sum of 2 quarters · filed 2016-10-28 | -$203.20M 10-Q · filed 2016-10-28 | -$124.30M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | -$39.90M 10-Q · filed 2016-07-28 | -$58.20M 10-Q · filed 2016-07-28 | $20.70M derived: sum of 3 quarters · filed 2017-02-21 | -$70.90M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | -$18.30M 10-Q · filed 2015-04-30 | $60.60M derived: sum of 2 quarters · filed 2017-02-21 | -$31.00M derived: sum of 3 quarters · filed 2017-02-21 | -$104.70M derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $78.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | -$12.70M derived: sum of 2 quarters · filed 2017-02-21 | -$86.40M derived: sum of 3 quarters · filed 2017-02-21 | -$162.20M 10-K · filed 2017-02-21 |
| 2014-09-30 | -$91.60M 10-Q · filed 2015-10-30 | -$165.30M derived: sum of 2 quarters · filed 2015-10-30 | -$241.10M 10-Q · filed 2015-10-30 | -$31.60M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | -$73.70M 10-Q · filed 2015-07-30 | -$149.50M 10-Q · filed 2015-07-30 | $60.00M derived: sum of 3 quarters · filed 2016-02-19 | $60.60M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | -$75.80M 10-Q · filed 2015-04-30 | $133.70M derived: sum of 2 quarters · filed 2016-02-19 | $134.30M derived: sum of 3 quarters · filed 2016-02-19 | $133.50M derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | $209.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $210.10M derived: sum of 2 quarters · filed 2016-02-19 | $209.30M derived: sum of 3 quarters · filed 2016-02-19 | $204.30M 10-K · filed 2016-02-19 |
| 2013-09-30 | $600.00K 10-Q · filed 2014-10-29 | -$200.00K derived: sum of 2 quarters · filed 2014-10-29 | -$5.20M 10-Q · filed 2014-10-29 | |
| 2013-06-30 | -$800.00K 10-Q · filed 2014-07-28 | -$5.80M 10-Q · filed 2014-07-28 | ||
| 2012-12-31 | $88.50M 10-K · filed 2015-02-19 | |||
| 2011-12-31 | -$178.50M 10-K · filed 2014-02-19 | |||
| 2010-12-31 | $80.80M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |